Evidence map›Paper›PMID 35962348›Full record

ArticleThe journal of headache and pain2022

Post-COVID-19 neuropsychiatric manifestations among COVID-19 survivors suffering from migraine: a case-control study.

Rehab Magdy, Alaa Elmazny, Shaimaa H Soliman, Eman H Elsebaie, Sara H Ali, Ali M Abdel Fattah, Mahmoud Hassan, Ahmed Yassien, Noha A Mahfouz, Radwa M Elsayed and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The journal of headache and pain, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
6.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 41 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Beyond the acute: pain in long COVID survivors at 1.5 years.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Migraine with aura: less control over pain and fragrances?The journal of headache and pain · 2023
    Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 2 countries.

Rehab MagdyNeurology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
Alaa ElmaznyNeurology Department, Faculty of Medicine, Cairo University, Cairo, Egypt.
Shaimaa H SolimanNeurology Department, Faculty of Medicine, Cairo University, Cairo, Egypt. shoshosoliman@yahoo.com.
Eman H ElsebaieDepartment of Public Health and Community Medicine, Faculty of Medicine, Cairo University, Cairo, Egypt.
Sara H AliDepartment of Otolaryngology, Faculty of Medicine, Beni-Suef University, Beni- Suef, Egypt.
Ali M Abdel FattahDepartment of Gastroenterology, Hepatology, and Endemic Medicine, Faculty of Medicine, Beni-Suef University, Beni- Suef, Egypt.
Mahmoud HassanDepartment of Internal Medicine, Faculty of Medicine, Beni-Suef University, Beni- Suef, Egypt.
Ahmed YassienDepartment of Critical Care Medicine, Beni-Suef University, Beni-Suef, Egypt.
Noha A MahfouzDepartment of Psychiatry Faculty of Medicine, Cairo University, Cairo, Egypt.
Radwa M ElsayedDepartment of Family Medicine, Faculty of Medicine, Cairo University, Cairo, Egypt.
Wael FathyDepartment of Anaesthesia, Surgical ICU and Pain Management, Beni-Suef University, Beni-Suef, Egypt.
Hoda M Abdel-HamidDepartment of Chest Diseases, Faculty of Medicine, Cairo University, Cairo, Egypt.
Jehan MohamedDepartment of Anaesthesia, Surgical ICU and Pain Management, Beni-Suef University, Beni-Suef, Egypt.
Mona HusseinNeurology department, Beni-Suef University, Beni-Suef, Egypt.
Beni-Suef University · EGCairo University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe burden of post-coronavirus disease (COVID)-19 symptoms has been increasing and is of great concern in patients with pre-existing chronic medical conditions.This study aimed to delineate the post-COVID-19 neuropsychiatric symptoms among migraine patients compared to the non-migraine control group.

methodsTwo groups, each of 204 COVID-19 survivors, were enrolled in the study after 3 months of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, one group fulfilling the episodic migraine criteria and the other serving as a matching control group. Subjects were evaluated through an in-person interview for post-COVID-19 neuropsychiatric symptoms, including detailed headache patterns and severity, using the visual analogue scale.

resultsThe Frequency of headache during the acute phase of COVID-19 was more frequent in migraine patients (OR = 1.60, 95%CI = 1.04-2.45, P-value = 0.031). The reported significant post-COVID-19 neuropsychiatric symptoms in migraine patients compared to controls were fatigue (OR = 1.662, 95%CI = 1.064-2.596, P-value = 0.025), anosmia/hyposmia (OR = 2.06, 95%CI = 1.164- 3.645, P-value = 0.012), cacosmia (OR = 2.663, 95%CI = 1.145-6.195, P-value = 0.019), depression (OR = 2.259, 95%CI = 1.284- 3.975, P-value = 0.004), anxiety (OR = 3.267, 95%CI = 1.747- 6.108, P-value ≤ 0.001), insomnia (OR = 2.203, 95%CI = 1.298- 3.739, P-value = 0.003), and headache (OR = 3.148, 95%CI = 1.616-6.136, P-value =  ≤ 0.001).While there was no statistically significant difference between migraine patients and controls regarding the post-COVID-19 functional status score (P-value = 0.102). The pattern of post-COVID-19 headache was reported as chronic headache transformation in 17.6% of the migraine group, with the median intensity rate being 5.5 and IQR (3-7). In the control group, 14% experienced chronic headache attributed to systemic viral infection with a median intensity rate of 2 and IQR (2-5), while 12% experienced a new daily persistent headache with a median intensity of 5 and IQR (1-6).

conclusionThe study highlighted the importance of follow-up migraine patients upon recovery from COVID-19 infection, being more vulnerable to post-COVID-19 symptoms.

Indexed as

COVID-19Migraine DisordersCase-Control StudiesHeadacheHumansSARS-CoV-2SurvivorsHeadacheLong COVID-19MigraineNeuropsychiatric symptomsSARS-CoV-2

Identifiers

PMID35962348
PMCPMC9372973
OpenAlexW4291145617

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.